<DOC>
	<DOCNO>NCT00658619</DOCNO>
	<brief_summary>Stage 1 patient-masked , dose-escalation , safety evaluation brimonidine intravitreal implant . Patients receive implant one eye `` sham '' treatment ( mean treatment ) fellow eye . Stage 2 begin 1 month safety evaluate Stage 1 . Stage 2 randomize , double-masked , dose-response , sham-controlled evaluation safety efficacy brimonidine intravitreal implant patient geographic atrophy age-related macular degeneration . Patients follow 2 year .</brief_summary>
	<brief_title>Safety Efficacy Brimonidine Intravitreal Implant Patients With Geographic Atrophy Due Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Geographic atrophy eye due agerelated macular degeneration Visual acuity 20/40 20/320 Known allergy brimonidine Uncontrolled systemic disease infection eye Recent eye surgery injection eye Female patient pregnant , nurse planning pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>